J Sieper Selected Research

Ankylosing Spondylitis

1/2019	Spinal radiographic progression over 2 years in ankylosing spondylitis patients treated with secukinumab: a historical cohort comparison.
3/2017	[Evidence-based recommendations on diagnostics and therapy of axial spondyloarthritis : S3 guidelines of the German Society of Rheumatology (DGRh) in cooperation with the Association of the Scientific Medical Societies in Germany (AWMF)].
1/2017	Secukinumab and Sustained Improvement in Signs and Symptoms of Patients With Active Ankylosing Spondylitis Through Two Years: Results From a Phase III Study.
1/2016	Long-term efficiency of infliximab in patients with ankylosing spondylitis: real life data confirm the potential for dose reduction.
10/2015	Impact of Certolizumab Pegol on Patient-Reported Outcomes in Patients With Axial Spondyloarthritis.
3/2015	Effect of certolizumab pegol over ninety-six weeks in patients with axial spondyloarthritis: results from a phase III randomized trial.
1/2015	In situ analysis of interleukin-6 expression at different sites of zygapophyseal joints from patients with ankylosing spondylitis in comparison to controls.
11/2014	Long-Term Maintenance of Improvements in Patient-Reported Outcomes With Certolizumab Pegol in Patients With Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis: 96-Week Results of the Rapid-Axspa Study.
9/2014	[German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 8.4 Pharmaceutical therapy, 8.5 Evaluation of therapy success of pharmaceutical measures].
9/2014	[German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 8 Therapy, 8.1 Treatment concept, 8.2 Therapy targets and strategy].

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

J Sieper Research Topics

Disease

85	Ankylosing Spondylitis 01/2019 - 02/2000
30	Necrosis 03/2016 - 04/2000
20	Axial Spondyloarthritis 11/2019 - 06/2009
18	Arthritis (Polyarthritis) 01/2011 - 01/2000
14	Inflammation (Inflammations) 01/2015 - 01/2000
14	Rheumatoid Arthritis 06/2014 - 04/2000
13	Psoriatic Arthritis 03/2016 - 02/2000
11	Back Pain (Backache) 01/2011 - 01/2000
8	Rheumatic Diseases (Rheumatism) 03/2016 - 11/2007
8	Pain (Aches) 07/2010 - 06/2003
8	Reactive Arthritis (Reiter Disease) 04/2003 - 01/2000
8	Spondylarthropathies 12/2002 - 04/2000
7	Sacroiliitis 01/2011 - 01/2000
6	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2011 - 07/2001
5	Ankylosis 07/2011 - 01/2000
4	Infections 01/2017 - 09/2000
4	Crohn Disease (Crohn's Disease) 01/2017 - 07/2001
4	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2014 - 05/2004
3	Spondylarthritis (Spinal Arthritis) 02/2020 - 06/2003
3	Uveitis 01/2016 - 01/2010
3	Osteoarthritis 01/2015 - 11/2000
3	Non-Radiographic Axial Spondyloarthritis 11/2014 - 07/2010
3	Anterior Uveitis 07/2010 - 05/2004
3	Body Weight (Weight, Body) 03/2008 - 04/2003
3	Osteoporosis 07/2001 - 04/2001
2	Fatigue 01/2017 - 12/2004
2	Chronic Disease (Chronic Diseases) 01/2017 - 03/2010
2	Systemic Lupus Erythematosus (Libman-Sacks Disease) 06/2014 - 01/2002
2	Myocarditis (Carditis) 01/2002 - 06/2000
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2017
1	Neoplasms (Cancer) 01/2017
1	Joint Diseases (Joint Disease) 01/2012
1	Hypersensitivity (Allergy) 07/2011
1	Iritis 01/2010
1	Iridocyclitis 01/2010
1	Ulcerative Colitis 05/2007
1	Injection Site Reaction 12/2004

Drug/Important Bio-Agent (IBA)

33	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2016 - 04/2000
27	Infliximab (Remicade)FDA Link 01/2016 - 06/2000
16	Etanercept (Enbrel)FDA Link 07/2011 - 07/2001
11	Biological ProductsIBA 01/2019 - 07/2001
11	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 01/2019 - 01/2000
11	CytokinesIBA 01/2015 - 04/2000
10	Sulfasalazine (Azulfidine)FDA LinkGeneric 07/2011 - 01/2002
9	C-Reactive ProteinIBA 01/2017 - 06/2003
8	Tumor Necrosis Factor InhibitorsIBA 02/2020 - 09/2004
8	HLA-B27 Antigen (HLA B27 Antigen)IBA 06/2011 - 04/2000
7	Antirheumatic Agents (DMARD)IBA 01/2012 - 11/2002
7	O,O-diisopropyl-S-benzylthiophosphate (IBP)IBA 07/2010 - 01/2000
6	AntigensIBA 01/2011 - 04/2000
6	Interferon-gamma (Interferon, gamma)IBA 11/2008 - 04/2000
5	Certolizumab Pegol FDA Link 01/2016 - 01/2014
5	Proteins (Proteins, Gene)FDA Link 06/2014 - 07/2003
5	Methotrexate (Mexate)FDA LinkGeneric 09/2010 - 04/2000
5	Interleukin-10 (Interleukin 10)IBA 06/2006 - 04/2000
5	Monoclonal AntibodiesIBA 05/2005 - 06/2000
4	Pharmaceutical PreparationsIBA 11/2019 - 01/2002
4	AntibodiesIBA 01/2016 - 09/2000
4	SteroidsIBA 03/2006 - 04/2001
4	Gadolinium DTPA (Magnevist)FDA Link 05/2005 - 02/2000
3	InterleukinsIBA 01/2015 - 06/2002
3	Adalimumab (Humira)FDA Link 08/2013 - 05/2005
3	Interleukin-4 (Interleukin 4)IBA 07/2003 - 04/2000
3	Anti-Bacterial Agents (Antibiotics)IBA 04/2003 - 04/2000
2	secukinumabIBA 01/2019 - 01/2017
2	Interleukin-6 (Interleukin 6)IBA 01/2015 - 06/2006
2	AutoantibodiesIBA 06/2014 - 01/2002
2	AutoantigensIBA 06/2014 - 07/2003
2	Naproxen (Naprosyn)FDA LinkGeneric 01/2014 - 01/2014
2	Prednisolone (Predate)FDA LinkGeneric 01/2014 - 01/2002
2	Therapeutic UsesIBA 03/2007 - 02/2005
2	Aligeron (AS 2)IBA 12/2006 - 08/2005
2	Aggrecans (Aggrecan)IBA 05/2005 - 07/2003
2	Interleukin-1 Receptors (Interleukin 1 Receptor)IBA 02/2005 - 11/2000
2	Acute-Phase Proteins (Acute-Phase Protein)IBA 12/2004 - 09/2003
2	GlucocorticoidsIBA 07/2001 - 04/2001
1	golimumab FDA Link 10/2015
1	Biomarkers (Surrogate Marker)IBA 06/2012
1	N 30IBA 07/2011
1	Histocompatibility Antigens Class IIBA 06/2011
1	Abatacept (Orencia)FDA Link 06/2011
1	Rituximab (Mabthera)FDA Link 05/2010
1	Virulence Factors (Pathogenicity Factors)IBA 11/2008
1	Diclofenac (SR 38)FDA LinkGeneric 03/2008
1	Celecoxib (Celebrex)FDA Link 03/2008
1	ParaffinIBA 06/2006
1	Transforming Growth Factor beta1 (TGF beta 1)IBA 06/2006
1	Transforming Growth Factor beta (TGF-beta)IBA 06/2006
1	Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA 12/2005
1	Interleukin-1 (Interleukin 1)IBA 02/2005
1	Interleukin 1 Receptor Antagonist Protein (Anakinra)FDA Link 02/2005
1	Leflunomide (Arava)FDA LinkGeneric 01/2005

Therapy/Procedure

41	Therapeutics 11/2019 - 04/2000
2	Contraindications 03/2006 - 09/2003
2	Biological Therapy 05/2005 - 09/2003
1	Drug Tapering 01/2016
1	Retreatment 08/2013
1	Secondary Prevention 01/2012
1	Subcutaneous Injections 03/2007
1	Withholding Treatment 02/2006